CONFERENCE ROUNDUP

Fewer injections with brolucizumab needed to achieve sustained dryness in wet AMD

Fewer brolucizumab (Beovu; Novartis) injections were required to achieve sustained dryness over 96 weeks in patients with wet AMD compared with aflibercept, according to a presentation at the 2020 ASRS Virtual Meeting. Patients treated with brolucizumab achieved sustained dryness faster and more frequently. A post-hoc analysis of the HAWK and...